Agranulocytosis Induced by Tamoxifen in a Breast Cancer Patient
Conclusion: Agranulocytosis is a very rare adverse event of tamoxifen.Breast Care (Source: Breast Care)
Source: Breast Care - June 20, 2019 Category: Cancer & Oncology Source Type: research

Meetings and Conferences
Breast Care 2019;14:184 –184 (Source: Breast Care)
Source: Breast Care - June 20, 2019 Category: Cancer & Oncology Source Type: research

PharmaNews
Breast Care 2019;14:181 –183 (Source: Breast Care)
Source: Breast Care - June 20, 2019 Category: Cancer & Oncology Source Type: research

Application of Periareolar Mammaplasty with the Tissue Folding Technique in Breast Reshaping following Polyacrylamide Hydrogel Removal
Conclusions: PMTFT provides satisfactory postoperative breast shape results. Economical, practical, and technical advantages were found over traditional prosthesis-mediated breast reconstruction. PMTFT can be an ideal surgical choice in appropriate cases.Breast Care (Source: Breast Care)
Source: Breast Care - June 11, 2019 Category: Cancer & Oncology Source Type: research

Challenges in Radiotherapy
Breast Care (Source: Breast Care)
Source: Breast Care - June 4, 2019 Category: Cancer & Oncology Source Type: research

Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620
Breast Care (Source: Breast Care)
Source: Breast Care - June 4, 2019 Category: Cancer & Oncology Source Type: research

Digital Analysis in Breast Imaging
Breast imaging is a multimodal approach that plays an essential role in the diagnosis of breast cancer. Mammography, sonography, magnetic resonance, and image-guided biopsy are imaging techniques used to search for malignant changes in the breast or precursors of malignant changes in, e.g., screening programs or follow-ups after breast cancer treatment. However, these methods still have some disadvantages such as interobserver variability and the mammography sensitivity in women with radiologically dense breasts. In order to overcome these difficulties and decrease the number of false positive findings, improvements in ima...
Source: Breast Care - June 4, 2019 Category: Cancer & Oncology Source Type: research

Digitalization in Medicine: It Is Our Chance and Responsibility Now to Shape the Digital Future of Breast Cancer Management
Breast Care (Source: Breast Care)
Source: Breast Care - June 3, 2019 Category: Cancer & Oncology Source Type: research

Individualized eHealth Support for Oncological Therapy Management
eHealth support for oncological therapy management has different faces. In addition to the direct support of therapy-supportive measures such as the promotion of physical activities, monitoring of the diet and observation of the quality of life through eHealth approaches are possible. Many solutions are now in transition between research and routine use. The most substantial evidence today is in the area of symptom monitoring. Independent studies have shown a significant survival benefit among other advantages as well. There is also a good overlap in eHealth and physical activity. More and more solutions are coming onto th...
Source: Breast Care - May 29, 2019 Category: Cancer & Oncology Source Type: research

Clinicopathological Analysis of 90 Cases of Polyacrylamide Hydrogel Injection for Breast Augmentation Including 2 Cases Followed by Breast Cancer
Conclusion: The long-term complications of PAAG-injected breast augmentation are various and complex. Pathologically, these complications are associated with foreign body reaction, fibrosis, and inflammation.Breast Care (Source: Breast Care)
Source: Breast Care - May 29, 2019 Category: Cancer & Oncology Source Type: research

Adherence and Persistence to Adjuvant Hormonal Therapy in Early-Stage Breast Cancer Patients: A Population-Based Retrospective Cohort Study in Israel
Conclusion: Adherence and persistence with HT among Israeli breast cancer survivors are comparable to those in international reports. Interventions are necessary to identify and prevent suboptimal HT adherence.Breast Care (Source: Breast Care)
Source: Breast Care - May 29, 2019 Category: Cancer & Oncology Source Type: research

A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer
Many analyses of the efficacy of neoadjuvant treatment (NAT) for early breast cancer including a meta-analysis derived from 10 randomized trials came to the conclusion that patients who would achieve pathologic complete response (pCR) following NAT would experience significant improvement in disease-free and overall survival (OS). Thus, pCR was proposed as a surrogate endpoint for OS, with pCR representing a robust prognostic marker for survival at an individual level. In the current analysis, we argue that OS following NAT-induced pCR might have reflected the initial prognosis of patients mainly defined – among othe...
Source: Breast Care - May 27, 2019 Category: Cancer & Oncology Source Type: research

Apps and More: Potentials of Digitalization in Breast Medicine
Digitalization in medicine is already being welcomed by some as a revolution and a deliverance, while others are still tending to take a more critical view of it. Digital tools are certainly still unfamiliar to the majority of physicians, and their potential benefits may not be immediately clear. As digitalization continues to advance, however, several exciting developments are emerging that may also be of interest in gynecology, and in particular for gynecological oncology and breast medicine. This note aims to outline a few examples in three areas: wearables, telemedicine, and “big data.” Two other areas of d...
Source: Breast Care - May 21, 2019 Category: Cancer & Oncology Source Type: research

Local Control of Breast Conservation Therapy versus Mastectomy in Multifocal or Multicentric Breast Cancer: A Systematic Review and Meta-Analysis
Conclusion: The LR of BCT for patients with MF/MC breast cancer was higher than that of BCT for patients with unifocal breast cancer. However, no significant difference was found in the incidence of LR between the BCT group and the mastectomy group in patients with MF/MC breast cancer.Breast Care (Source: Breast Care)
Source: Breast Care - May 8, 2019 Category: Cancer & Oncology Source Type: research

Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Breast Cancer: Do We Need a Delayed Image?
Conclusions: Delayed lymphoscintigraphy was useful in about 50% of the breast cancer patients in whom immediate scintigraphy failed to demonstrate a sentinel lymph node.Breast Care (Source: Breast Care)
Source: Breast Care - May 5, 2019 Category: Cancer & Oncology Source Type: research

Effectiveness and Safety of Implant-Based Breast Reconstruction in Locally Advanced Breast Carcinoma: A Matched Case-Control Study
Conclusion: Immediate IBBR may be a safe and effective surgical procedure in selected patients with LABC.Breast Care (Source: Breast Care)
Source: Breast Care - May 5, 2019 Category: Cancer & Oncology Source Type: research

BreastConsent 2
Breast Care 2019;14:I –IV (Source: Breast Care)
Source: Breast Care - April 24, 2019 Category: Cancer & Oncology Source Type: research

PharmaNews
Breast Care 2019;14:124 –124 (Source: Breast Care)
Source: Breast Care - April 24, 2019 Category: Cancer & Oncology Source Type: research

Meetings and Conferences
Breast Care 2019;14:125 –126 (Source: Breast Care)
Source: Breast Care - April 24, 2019 Category: Cancer & Oncology Source Type: research

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2 – Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.Breast Care (Source: Breast Care)
Source: Breast Care - April 18, 2019 Category: Cancer & Oncology Source Type: research

St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
This year, the St. Gallen Consensus Conference on early breast cancer treatment standards took place for the third time in Vienna, Austria, which is where the next conference will also take place (next date: March 17 –20, 2021!). Once again, more than 3,000 participants from over 100 countries came together, and, overall, the 2019 St. Gallen/Vienna conference was a great success. After 3 days of reviews conducted by a global faculty concerning the most important evidence published in the last 2 years, the Cons ensus votes’ challenge was to define the impact on routine everyday practice. This year, the conferenc...
Source: Breast Care - April 15, 2019 Category: Cancer & Oncology Source Type: research

Luminal Metastatic Breast Cancer
Breast Care (Source: Breast Care)
Source: Breast Care - April 15, 2019 Category: Cancer & Oncology Source Type: research

Prevention and Management of Chemotherapy-Induced Polyneuropathy
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a severe and common side effect caused by a variety of antineoplastic agents. Approximately 30 –40% of patients treated with agents such as taxanes, vinca alkaloids, or platinum derivatives will develop CIPN. CIPN presents predominantly as a sensory axonal neuro(no)pathy with occasional motor and autonomic dysfunction exhibiting considerable variability of clinical symptoms ranging from mil d tingling sensation to severe neuropathic pain. Typical symptoms include numbness (“minus symptom”), weakness, and abnormal gait as well as paresthesia and pain ...
Source: Breast Care - April 15, 2019 Category: Cancer & Oncology Source Type: research

Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors
Cyclin-dependent kinase (CDK) 4/6 inhibitors have become standard of care in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. They have been shown to double the efficacy of endocrine-based treatment. Three oral agents are available to date: palbociclib, ribociclib, and abemaciclib. The aim of this article is to give a short overview of the existing efficacy data, to summarize the recommended clinical monitoring procedures for patients under CDK4/6 inhibitors, and to shed light on the clinical management of the most common treatment-emergent adverse even...
Source: Breast Care - March 31, 2019 Category: Cancer & Oncology Source Type: research

Supportive Care – Different Agents and Strategies in the Combat against Toxicities in Anticancer Therapy
Breast Care (Source: Breast Care)
Source: Breast Care - March 31, 2019 Category: Cancer & Oncology Source Type: research

Hematopoietic Growth Factors in the Management of Anemia and Febrile Neutropenia
Chemotherapy-induced anemia (CIA) in cancer patients correlates with poor performance status and decreased quality of life. Currently recommended causal therapies are erythropoiesis-stimulating agents (epoetins), iron substitution, or a combination of both. Guidelines recommend considering red blood cell (RBC) transfusions for symptomatic anemia at a hemoglobin (Hb) level of (Source: Breast Care)
Source: Breast Care - March 14, 2019 Category: Cancer & Oncology Source Type: research

Location and Frequency of Residual Breast Tissue after Mastectomy
Conclusion: Mastectomy has a high probability of residual breast tissue being left behind. Physicians should be aware of this and act accordingly when planning surgical or follow-up treatment.Breast Care (Source: Breast Care)
Source: Breast Care - March 14, 2019 Category: Cancer & Oncology Source Type: research

What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
The introduction of biosimilars of biological agents for which the patents and exclusivity periods have expired is an attractive way of reducing healthcare spending through price competition with the reference product. In oncology, biosimilars of growth factors for supportive therapy were the pioneers; now, monoclonal antibody biosimilars are conquering the market. In Europe, this is currently limited to biosimilars of the monoclonal antibodies trastuzumab and rituximab. However, the pipeline is full and several monoclonal antibody biosimilars in oncology are now in late-stage development. We are expecting not only more bi...
Source: Breast Care - March 7, 2019 Category: Cancer & Oncology Source Type: research

Meetings and Conferences
Breast Care 2019;14:67-68 (Source: Breast Care)
Source: Breast Care - March 7, 2019 Category: Cancer & Oncology Source Type: research

Title Page / Table of Contents
Breast Care 2019;14:I-VI (Source: Breast Care)
Source: Breast Care - March 7, 2019 Category: Cancer & Oncology Source Type: research

PharmaNews
Breast Care 2019;14:64-65 (Source: Breast Care)
Source: Breast Care - March 7, 2019 Category: Cancer & Oncology Source Type: research

PharmaNews
Breast Care 2019;14:63 (Source: Breast Care)
Source: Breast Care - March 7, 2019 Category: Cancer & Oncology Source Type: research

Comparison of Subpectoral versus Prepectoral Immediate Implant Reconstruction after Skin- and Nipple-Sparing Mastectomy in Breast Cancer Patients: A Retrospective Hospital-Based Cohort Study
Introduction: Implant-based immediate breast reconstruction (IBR) is a common surgical procedure in breast cancer patients. Comparative analysis concerning the placement of implants is still lacking. Hence, we aimed to analyze pre- versus subpectoral IBR in breast cancer patients.Patients: A single-center experience with implant-based IBR following skin/nipple-sparing mastectomy was evaluated. Patient demographics, incidence of major complications, and quality of life assessed with BREAST-Q were compared between the pre- and subpectoral cohort.Results: A total of 63 patients were included in this analysis of whom 29 underw...
Source: Breast Care - February 25, 2019 Category: Cancer & Oncology Source Type: research

Patient-Reported Satisfaction after Prophylactic Operations of the Breast
Conclusions: Prophylactic mastectomy is a procedure with risk for long-term complications in some cases. Our results confirm high satisfaction with the decision and improved quality of life.Breast Care (Source: Breast Care)
Source: Breast Care - February 14, 2019 Category: Cancer & Oncology Source Type: research

Long-Term Side Effects of Adjuvant Therapy in Primary Breast Cancer Patients: Results of a Web-Based Survey
Conclusion: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.Breast Care (Source: Breast Care)
Source: Breast Care - February 14, 2019 Category: Cancer & Oncology Source Type: research

Prophylaxis and Management of Skin Toxicities
Skin toxicity is a common problem not only when treating breast cancer but in all cancer types. Visible on the surface, these side effects come not just with burdening symptoms but also with stigmatization. With increasing diversity in therapeutic options, dermatologic side effects are also becoming increasingly complex and more challenging for the clinician. We reviewed the most common dermatologic side effects of current anticancer therapy, including toxicity induced by chemotherapy, targeted therapy, and immunotherapy. In particular, we focus on xerosis and pruritus, (acneiform) exanthema, hand-foot syndrome, nail toxic...
Source: Breast Care - February 14, 2019 Category: Cancer & Oncology Source Type: research

News from the San Antonio Breast Cancer Symposium 2018
Breast Care (Source: Breast Care)
Source: Breast Care - February 12, 2019 Category: Cancer & Oncology Source Type: research

What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology
The introduction of biosimilars of biological agents for which the patents and exclusivity periods have expired is an attractive way of reducing healthcare spending through price competition with the reference product. In oncology, biosimilars of growth factors for supportive therapy were the pioneers; now, monoclonal antibody biosimilars are conquering the market. In Europe, this is currently limited to biosimilars of the monoclonal antibodies trastuzumab and rituximab. However, the pipeline is full and several monoclonal antibody biosimilars in oncology are now in late-stage development. We are expecting not only more bi...
Source: Breast Care - February 12, 2019 Category: Cancer & Oncology Source Type: research

ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany
Conclusion: Fulvestrant 500 mg was administered successfully to patients under daily practice conditions, and both medications were well tolerated. TTP was longest in patients treated with fulvestrant 500 mg 1 L compared with 2 L and 3 L in the palliative care setting.Breast Care (Source: Breast Care)
Source: Breast Care - February 8, 2019 Category: Cancer & Oncology Source Type: research

Emulsion of Olive Oil and Calcium Hydroxide for the Prevention of Radiation Dermatitis in Hypofractionation Post-Mastectomy Radiotherapy: A Randomized Controlled Trial
Conclusions: Addition of an emulsion of olive oil and calcium hydroxide for patients undergoing hypofractionation PMRT yielded superior preventive results over a general skin care regimen alone, in terms of delaying skin toxicity, reducing the severity of acute radiation dermatitis, and a better quality of life in the intervention group. However, a larger number of patients will be required to confirm this result.Breast Care (Source: Breast Care)
Source: Breast Care - February 4, 2019 Category: Cancer & Oncology Source Type: research

Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy
Conclusion: The administration of trastuzumab should be considered standard treatment for HER2-positive patients who have achieved pCR after NACT alone.Breast Care (Source: Breast Care)
Source: Breast Care - February 4, 2019 Category: Cancer & Oncology Source Type: research

Promoter Methylation Status of the Retinoic Acid Receptor-Beta 2 Gene in Breast Cancer Patients: A Case Control Study and Systematic Review
Conclusion: We found a higher frequency ofRAR β2 gene methylation in the blood and cancer tissues of patients compared to the blood of controls and adjacent normal breast tissues. The survey of studies on various populations demonstrated a higherRAR β2 methylation frequency in breast cancer patients compared to normal individuals, and many reports suggest a significant association between hypermethylation of the gene and susceptibility to breast cancer.Breast Care (Source: Breast Care)
Source: Breast Care - January 31, 2019 Category: Cancer & Oncology Source Type: research

Recurrence of Primary Breast Angiosarcoma 7 Years after Mastectomy in a 17-Year-Old Woman: A Case Report
Conclusions: This is a rare case as the patient was below 18 years old and the follow-up was greater than 5 years. Taken together, long-term close follow-up is extremely important, regardless of how long after surgery and the status of the surgical margins.Breast Care (Source: Breast Care)
Source: Breast Care - January 31, 2019 Category: Cancer & Oncology Source Type: research

Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study
Conclusion: The predictive value for a suspicious breast lesion in CBEs performed by MTEs in patients without prior surgery was similar to that of physician-conducted CBEs. Including MTEs in the CBE procedure in breast units thus appears feasible and could be a way of utilizing their skills.Breast Care (Source: Breast Care)
Source: Breast Care - January 31, 2019 Category: Cancer & Oncology Source Type: research

Biosimilar Trastuzumab in Clinical Trials: Differences or Not
In the last decade, cancer therapies have increasingly taken the form of combination treatments in which biologic agents play a crucial role. In breast cancer, the treatment strategy is adjusted to intrinsic subtypes such as human epidermal growth factor receptor-2(HER2)-positive. With the introduction of trastuzumab, a monoclonal antibody against HER2, survival has significantly improved in early and metastatic breast cancer. Trastuzumab's patent has now expired and biosimilars are moving into the market. Several clinical trials have led to the approval of 5 different biosimilar trastuzumabs. Results proved similarity bet...
Source: Breast Care - January 31, 2019 Category: Cancer & Oncology Source Type: research

Position of Scientific Oncological Societies Towards Biosimilar Antibodies
First biosimilars of monoclonal antibodies have recently been approved in oncology. Biosimilars enable economic competition, alleviate the financial burden for insurances, and may facilitate access to these drugs in low-income countries. Biosimilars are not completely identical to the original drug. The approval of biosimilars is only partially based on results of randomized clinical studies. In the introduction phase of new biosimilars, this can lead to uncertainties for patients and physicians. Based on the current clinical data and experiences, biosimilars of monoclonal antibodies in oncology show no significant differe...
Source: Breast Care - January 14, 2019 Category: Cancer & Oncology Source Type: research

Approval by Authorities Does not Allow For Suboptimal Study Conduct but Offers New Academic Possibilities
Breast Care (Source: Breast Care)
Source: Breast Care - January 14, 2019 Category: Cancer & Oncology Source Type: research

Breastconsent 1
Breast Care 2018;13:I-IV (Source: Breast Care)
Source: Breast Care - December 20, 2018 Category: Cancer & Oncology Source Type: research

Acknowledgement to Reviewers
Breast Care 2018;13:399 (Source: Breast Care)
Source: Breast Care - December 19, 2018 Category: Cancer & Oncology Source Type: research

Contents Vol. 13, 2018
Breast Care 2018;13:473-476 (Source: Breast Care)
Source: Breast Care - December 19, 2018 Category: Cancer & Oncology Source Type: research